morphology mimics, such as thrombotic microangiopathy, disseminated intravascular coagulation, and CNI nephrotoxicity. The morphology mimics either hyperacute rejection or accelerated acute rejection. Hemodialysis treatment commenced. During hospitalization, the dose of tacrolimus started at 6 mg/d, increased to 8 mg/d on December 4 for 1 day, and has remained at 4 mg/d since December 5, 2014 after occurrence of graft loss due to the acute AMR.
Although interaction between RFP and CNIs has been well discussed in the literature, the unique aspect of the current report is that it represents the most dramatic case of rapid-onset acute AMR concurrent with TB and the initiation of therapy. The rapid-onset of acute rejection occurring within 1 day after drug use is unusual. It is possible that both the immune reaction triggered by TB itself and the effect of tacrolimus play an important role in the process. It can also be argued that the rejection was a process in evolution at the time of TB diagnosis; however, his renal function, which was relatively stable before the onset of rejection with creatinine of around 2 mg/dL for several months, is evidence to support that the process was not in progress at the time of TB diagnosis. The limitation of this case report is that the serum tacrolimus level was not closely monitored and the dose was not increased accordingly.
The current case re-emphasizes the importance of prevention and treatment of TB infection in kidney transplantation. To avoid reactivation of latent TB infection after immunosuppressive therapy, diagnosis, and treatment of latent TB are strongly recommended during the pretransplantation period [1] . To treat active TB infection after transplantation, RFP should be avoided [2] , and use of RFP-sparing protocols is highly suggested [3] . Although preexisting TB is deemed a contraindication to transplantation, several reports have demonstrated that pre- existing TB in patients undergoing transplantation can be managed successfully [4] . If RFP is prescribed, increase in the dose of CNI, and close monitoring of the trough CNI level is essential. The dose of tacrolimus should be increased (even to 2e10 times of the original doses) based on serum levels of tacrolimus in patients receiving RFP therapy [5] .
